S3 Characterizing Treatment Satisfaction and Health-Related Quality of Life of Patients With Exocrine Pancreatic Insufficiency Taking Pancreatic Enzyme Replacement Therapy: Findings From the PACT-CP Registry

Introduction: Pancreatic enzyme replacement therapy (PERT) is the mainstay of exocrine pancreatic insufficiency (EPI) treatment. Frequently, patients (pts) receiving PERT may have multiple comorbidities requiring polypharmacy, which can contribute to pill burden, influence treatment satisfaction, impact PERT adherence, and negatively affect health-related quality of life (HRQoL). The aim of this study was to assess these factors or aspects in pts with EPI with chronic pancreatitis or recurrent acute pancreatitis. Methods: The U.S.-based PAtient-CenTric Chronic Pancreatitis (PACT-CP) registry (NCT05762445) is a prospective, pt-driven registry designed to understand the unmet needs/burden of pts with EPI. Data were obtained from adults with suspected/confirmed EPI, a chronic pancreatitis/recurrent acute pancreatitis diagnosis, and taking PERT. Clinical characteristics, PERT use, treatment satisfaction (using the Treatment Satisfaction Questionnaire for Medication-9), and HRQoL (using physical [PCS-12] and mental [MCS-12] health scores) were collected from pts and/or their healthcare providers. Data from baseline to 6 months in pts receiving PERT (pancrelipase, Zenpep® Delayed-Release Capsules) are reported. Results: Of 188 pts in the registry, 37 took PERT at enrollment/Visit 1. Mean (SD) age was 59.5 (10.1) years, and 20 pts were women (59%, n = 34). Anxiety (38%) and depression (38%) were commonly (>30%) reported medical histories; diabetes mellitus was reported in 19% of pts. At least 41% of pts were taking another type of medication. The most frequent clinical manifestations at 6 months were diarrhea (29%) and bloating (29%). Most pts took a median of 6 PERT capsules/day and reported PERT greatly or somewhat improved their symptoms at visits ≤6 months. Pts were generally satisfied with treatment convenience and effectiveness; global satisfaction appeared slightly increased over time. Mean (SD) PCS-12 scores appeared stable at the first (40.93 [10.06], n = 29) and 6-month (40.60 [9.77], n = 20) visits and showed a positive trend on the MCS-12 (42.28 [11.03] and 45.91 [11.37], respectively). Conclusion: Most pts had comorbidities and a high pill burden, which could adversely affect treatment satisfaction and HRQoL. One limitation is that PERT use at baseline adherence/persistence could not be confirmed. Better understanding of how treatment satisfaction impacts treatment adherence/persistence and, subsequently, disease control or clinical outcomes may ultimately help improve HRQoL and reduce healthcare resource utilization in pts with EPI.